Inactive Instrument

Paxman AB (publ) Stock Nasdaq Stockholm

Equities

SE0009806284

Medical Equipment, Supplies & Distribution

Financials

Sales 2023 210M 19.58M 26.89M Sales 2024 * 292M 27.21M 37.37M Capitalization 844M 78.66M 108M
Net income 2023 8M 745K 1.02M Net income 2024 * 34M 3.17M 4.35M EV / Sales 2023 3.33 x
Net cash position 2023 * 19M 1.77M 2.43M Net cash position 2024 * 42M 3.91M 5.37M EV / Sales 2024 * 2.75 x
P/E ratio 2023
83.6 x
P/E ratio 2024 *
24.7 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 36.29%
More Fundamentals * Assessed data
Dynamic Chart
Paxman AB Appoints Karen Giddings Clakely to the Board CI
Paxman AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Paxman AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Paxman AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
PAXMAN Announces Palmetto GBA Approves First Local Coverage Determination for Scalp Cooling Therapy CI
Paxman AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Paxman AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Paxman AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Paxman AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Paxman Scalp Cooling System Receives EU MDR Certification CI
Paxman AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Paxman AB Announces Its Selection by the SWOG Cancer Research Network for the Paxman Limb Cryocompression System to Be Used in A Prospectively Designed Study Looking At Prevention of Chemotherapy-Induced Peripheral Neuropathy CI
Paxman AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Paxman AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Paxman Launches Enhanced Provider and Patient Assistance Services, as Well as Offering A New Business Model to Health Systems CI
More news
Managers TitleAgeSince
Chief Executive Officer 41 16-12-19
Director of Finance/CFO 44 20-02-29
Chief Tech/Sci/R&D Officer 65 08-12-31
Members of the board TitleAgeSince
Director/Board Member 77 16-11-30
Chairman 70 16-11-30
Director/Board Member 56 16-12-19
More insiders
Paxman AB (publ) is a Sweden-based developer of scalp cooling technology. The cooling system aims to reduce the risk of hair loss connected with cytostatic treatment of cancer. The Company offers a stand-alone, mobile electric cooling unit, which markets under the name Paxman Scalp Cooler, which is a liquid-based cooling system that cools down the patients scalp through the silicone hat. The product has two versions - for one or two patients to be cooled at once. Each device contains a built-in touch screen with a menu-controlled graphic user interface to monitor the process. The lightweight system enables patient to participate in other activities. The Company’s primary markets are Great Britain, Scandinavian countries, the Netherlands, Belgium and Australia.
Calendar
More about the company